Design And Synthesis of Dual Action Antioxiodant-Inflammatory of Pde4 Agents for Chronic Disease.

Oxidative stress and inflammation are common features of chronic disorders such asthma, chronic obstructive pulmonary disease (COPD), and inflammatory ailments. A viable therapeutic strategy for the treatment of these intricate disorders is the development and manufacturing of dual-action compounds that target the antioxidant and anti-inflammatory pathways at the same time. Because of its anti-inflammatory properties, phosphodiesterase-4 (PDE-4) inhibitors have showed promise in the treatment of conditions like asthma and COPD. However, when paired with antioxidant qualities, which might lessen the oxidative damage linked to certain illnesses, their effectiveness might be increased. The design and production of new PDE-4 inhibitors with dual-action characteristics that target oxidative stress and inflammation are the main goals of this study. We seek to maximize these compounds’ potency, selectivity, and safety profile by utilizing molecular docking studies and structure-activity relationship (SAR) analysis. In vitro tests like DPPH and FRAP will be used to assess the antioxidant activity of the produced compounds, in addition to anti-inflammatory tests including leukocyte migration and cytokine production inhibition. Additionally, enzyme inhibition experiments will be used to verify their PDE-4 inhibitory efficacy. The ultimate objective is to create a therapeutic candidate that offers a safer and more effective treatment alternative by addressing the dual pathology of chronic diseases. Contributing to the creation of innovative, multipurpose therapeutic agents that enhance the treatment of chronic inflammatory illnesses is the goal of this effort.